<DOC>
	<DOCNO>NCT00003709</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness carbendazim treat patient advance solid tumor .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose oral carbendazim patient advance solid tumor . II . Determine qualitative quantitative toxic effect oral carbendazim patient . III . Characterize pharmacokinetic profile oral carbendazim patient . IV . Assess recommend dose oral carbendazim use phase II study . V. Determine preliminary evidence antitumor activity regimen patient . OUTLINE : This dose escalation study . Patients receive oral carbendazim weekly 3 week follow 1 week rest . Treatment repeat every 28 day absence disease progression unacceptable toxic effect . Cohorts 3-6 patient receive escalate dos carbendazim . If dose limit toxicity ( DLT ) see 1 3 patient treat give dose level , 3 additional patient enter dose level . Dose escalation continue maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience DLT . Patients follow 30 day posttreatment . PROJECTED ACCRUAL : Up 35 patient accrue study .</detailed_description>
	<mesh_term>Carbendazim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically proven advanced solid tumor standard therapy exists progress recur follow prior therapy Measurable evaluable disease No hematological malignancy ( e.g. , leukemia lymphoma ) No know brain leptomeningeal disease , unless lesion previously irradiate , currently treat corticosteroid , clinical symptom PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin le 1.5 mg/dL AST ALT great 2 time upper limit normal ( ULN ) ( great 5 time ULN due tumor ) PT aPTT great 1.5 time ULN Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : No unstable atrial ventricular arrhythmia require medication No ischemic event within 6 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No psychiatric disorder No history seizure disorder No severe concurrent disease No history ulcer abnormality would interfere carbendazim absorption No history hypersensitivity PEGformulated medication ( include cyclosporine etoposide ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week since prior nitrosoureas mitomycin ) recover No concurrent cytotoxic therapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy Surgery : No prior gastrointestinal surgery would interfere carbendazim absorption Other : No concurrent use phenytoin , phenobarbital , valproic acid , antiepileptic prophylaxis No concurrent schedule antacid , H2 blocker ( e.g. , cimetidine ranitidine ) hydrogen pump inhibitor ( e.g. , omeprazole ) , cisapride</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>